Ross River virus vaccine - Ology Bioservices

Drug Profile

Ross River virus vaccine - Ology Bioservices

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter Healthcare Corporation
  • Developer Nanotherapeutics
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ross River virus infections

Most Recent Events

  • 02 Oct 2017 Nanothearpeutics is now called Ology Bioservices
  • 23 Apr 2013 Baxter completes a phase III follow-up trial for Ross River virus infections in Australia (NCT01604746)
  • 31 Oct 2012 Baxter completes a phase III trial in Ross River virus infections in Australia (NCT01242670)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top